Indrayani Biotech Ltd (526445)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 7 அக். 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 6 நவ. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
சமீபத்திய காலாண்டு முடிவுகள் (Q1 FY27)
In its latest reported quarter, Q1 FY27, Indrayani Biotech's revenue was ₹37.7 Cr (+29.6% year on year, -48.2% on the previous quarter), and net profit ₹0.5 Cr (+237.5% year on year); the operating margin was 3.9%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹37.7 | +29.6% | -48.2% |
| செயல்பாட்டு லாபம் | ₹1.5 | -32.7% | -70.6% |
| நிகர லாபம் | ₹0.5 | +237.5% | -50.5% |
| EPS (₹) | 0.06 | +200.0% | -75.0% |
| செயல்பாட்டு லாப வரம்பு | 3.9% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Indrayani Biotech Limited submitted its Annual Report and Notice of the 34th Annual General Meeting for FY 2025-26 under Regulation 34(1). The Chairman's message highlights ongoing funding constraints over the past two years and notes that a Rights Issue was initiated in October 2026 to strengthen capitalization and support MSME aggregation. In FY26, the company generated Rs 172.84 Cr in revenue and Rs 2.27 Cr in net profit. The report also documents frequent turnover in key managerial roles, including multiple CFO and Company Secretary transitions during FY25-FY27.
- Submission of the 34th Annual General Meeting notice and Annual Report for FY 2025-26 under Regulation 34(1)
- Rights Issue was initiated in October 2026 to address funding constraints and mobilize growth capital
- Company saw three CFO changes between April 2025 and February 2026, with Kunisetty Venkateswara Rao appointed w.e.f. 27.02.2026
- Turnover in Company Secretary post with C.S. Shanmuga Sundar serving from 09.09.2026 till 02.11.2026
Indrayani Biotech has scheduled its 34th Annual General Meeting for November 30, 2026, with November 23, 2026, set as the cut-off date for e-voting. Notably, the Board has sought shareholder approval for material related-party transactions (RPTs) of up to Rs 25 crore each across six subsidiaries, totaling up to Rs 150 crore. Against the company's TTM revenue of Rs 181 crore and net worth of Rs 56 crore, these proposed RPT limits are substantial. The Board also approved the appointments of internal and secretarial auditors.
- 34th AGM scheduled for November 30, 2026; cut-off date for e-voting set for November 23, 2026.
- Proposed material related party transactions of up to Rs 25 crore each with 6 subsidiaries, totaling up to Rs 150 crore.
- Proposed total RPT limits of Rs 150 crore represent ~83% of TTM revenue (Rs 181 crore).
- Appointed M/s Vaithianathan & Associates as Internal Auditor and Ms. Nattery Srinivasan Poornima as Secretarial Auditor.
Indrayani Biotech Ltd has received listing approval from BSE for its proposed rights issue. The company has a current market capitalization of approximately Rs 80 crore and carries debt of Rs 59 crore against a net worth of Rs 56 crore (D/E of 1.06). While listing approval from the exchange is an important milestone, the specific issue size, rights entitlement ratio, and price were not disclosed in this filing.
- Received Listing Approval from BSE for proposed Rights Issue
- Current company market cap stands at Rs 80 Cr with debt of Rs 59 Cr
- Detailed terms including issue size and price were not disclosed in the filing extract
Indrayani Biotech approved the basis of allotment for 83,64,036 rights equity shares at an issue price of Rs 15 per share (including Rs 5 premium). Out of these, 75,03,333 shares were fully paid up at Rs 15, while 8,60,703 shares were allotted as partly paid at Rs 3.75 on application. Consequently, the paid-up equity capital increased from Rs 45.54 Cr to Rs 53.25 Cr. The total rights issue size represents roughly 15.6% of the company's Rs 80 Cr market capitalization.
- Approved allotment of 83,64,036 Rights Equity Shares at an issue price of Rs 15 each (face value Rs 10, premium Rs 5)
- 75,03,333 shares allotted as fully paid at Rs 15 per share
- 8,60,703 shares allotted as partly paid-up at Rs 3.75 per share on application
- Paid-up equity share capital increased from Rs 45,53,62,560 to Rs 53,25,47,648
Indrayani Biotech announced that its Board of Directors approved key secretarial changes effective November 02, 2026. The company appointed Ms. Nattery Srinivasan Poornima as Secretarial Auditor for FY 2025-26 to fill a casual vacancy following the resignation of Mr. K. Ravichandran on August 06, 2026. Additionally, the Board accepted the resignation of Mr. C.S. Shanmuga Sundar as Company Secretary and Compliance Officer due to health reasons after completing his 45-day notice period.
- Appointment of Ms. Nattery Srinivasan Poornima (CP No.: 24073 / Membership No.: F10786) as Secretarial Auditor for FY 2025-26
- Casual vacancy filled following the resignation of previous auditor Mr. K. Ravichandran on August 06, 2026
- Resignation of Mr. C.S. Shanmuga Sundar as Company Secretary & Compliance Officer effective close of business on November 02, 2026
- 45-day notice period completed following resignation submission on September 17, 2026
Indrayani Biotech has filed a formal response to the Income Tax Department against a recovery notice covering Assessment Years 2011-12 to 2013-14 totaling ₹1.17 Cr. For AY 2013-14, the company seeks deletion of a ₹98,09,000 demand, citing an ITAT order from November 2, 2020, that set aside the original rectification. For AY 2011-12 and 2012-13, regarding a ₹18,45,520 demand linked to excise duty disallowance, it has requested the recovery be kept in abeyance pending first appeal adjudication. The total disputed amount of ₹1.17 Cr represents about 39% of the company's TTM net profit of ₹3 Cr, but the company reports no immediate operational or financial impact.
- Responded to Income Tax Department recovery notice for AY 2011-12, 2012-13, and 2013-14
- Requested deletion of ₹98,09,000 demand for AY 2013-14, citing ITAT order dated 02.11.2020
- Requested abeyance on ₹18,45,520 demand for AY 2011-12 and 2012-13 pending First Appeal filed on 21.04.2022
- Total disputed demand amounts to ~₹1.17 Cr
Indrayani Biotech Limited has announced the resignation of Mr. K.S. Vaidyanathan (DIN: 01122393) from his position as an Independent Director, effective close of business hours on October 13, 2026. According to the filing, the resignation was tendered on October 12, 2026, due to personal reasons, with confirmation that no other material reasons exist. He holds no directorships or committee memberships in any other listed entities. The Rs 80 crore market cap company reported TTM revenue of Rs 181 crore and PAT of Rs 3 crore.
- Independent Director K.S. Vaidyanathan resigned vide letter dated October 12, 2026
- Board accepted the resignation with effect from close of business hours on October 13, 2026
- Reason cited is personal reasons with no other material reasons confirmed
- Holds Nil directorships and Nil committee memberships in other listed entities
Indrayani Biotech reported consolidated revenue from operations of ₹37.71 crore for Q1 FY27 (ended June 30, 2026), up 29.6% YoY from ₹29.10 crore in Q1 FY26. Consolidated net profit reached ₹0.54 crore compared to ₹0.16 crore in the same period last year. On a standalone basis, revenue fell 37.9% YoY to ₹4.15 crore, while standalone net profit came in at ₹0.15 crore. The company also reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees.
- Consolidated revenue from operations increased 29.6% YoY to ₹3,770.55 lakhs (₹37.71 crore)
- Consolidated profit after tax stood at ₹54.00 lakhs compared to ₹15.65 lakhs in Q1 FY26
- Profit attributable to owners of the company reported at ₹26.22 lakhs with basic EPS of ₹0.06
- Standalone revenue from operations dropped YoY to ₹415.34 lakhs from ₹668.57 lakhs
- Board approved reconstitution of Audit, Stakeholder Relationship, and Rights Issue Committees
Indrayani Biotech Limited has completed the sale of a 1.83% stake in its subsidiary, Dindigul Farm Product Limited, via the open market on September 30, 2026. Following this divestment, the company's holding in Dindigul Farm Product stands reduced to 27.05%. The subsidiary is a significant contributor to the group, generating Rs 90.04 Cr in turnover, which accounts for 65.33% of consolidated revenues. The exact sale proceeds and consideration amount were not quantified in the filing.
- Divested 1.83% shareholding/control in subsidiary Dindigul Farm Product Limited
- Post-disposal shareholding drops to 27.05%
- Dindigul Farm Product contributed turnover of Rs 90.04 Cr (65.33% of net worth/revenue) during the last financial year
- Transaction executed through open market sales with completion on September 30, 2026
Indrayani Biotech Ltd has scheduled a meeting of its Board of Directors on Wednesday, October 7, 2026. The board will consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. Additionally, the agenda includes a proposal for the reconstitution of various board committees. Investors will look to see if the company sustains its profitability following FY26 net profit of Rs 2.27 Cr.
- Board meeting scheduled for October 7, 2026
- Agenda includes approval of unaudited results for the quarter ended June 30, 2026
- Consolidated and Standalone financial results to be accompanied by Limited Review Report
- Proposal to reconstitute various Committees of the Board of Directors
Indrayani Biotech reported audited standalone revenue of ₹21.90 Cr (₹2,189.78 Lakhs) for FY26, down 42% YoY from ₹37.77 Cr in FY25. Standalone net profit declined 51.6% YoY to ₹0.70 Cr (₹69.97 Lakhs) with EPS dropping to ₹0.15 from ₹0.32 in FY25. Statutory auditors issued a qualified opinion on the consolidated results due to non-Ind AS accounting at two subsidiaries and unconfirmed balances in loans, receivables, and payables. Additionally, standalone cash flow from operations worsened sharply to negative ₹14.10 Cr in FY26.
- Standalone FY26 revenue from operations declined 42% YoY to ₹2,189.78 Lakhs from ₹3,776.91 Lakhs in FY25.
- Standalone net profit fell 51.6% YoY to ₹69.97 Lakhs, leading to an EPS of ₹0.15 compared to ₹0.32 in the previous year.
- Statutory auditors gave a qualified opinion on consolidated results citing Matrix Boilers and Kniss Laboratories reporting under Indian GAAP instead of Ind AS.
- Auditor flagged unconfirmed trade creditors of ₹61.83 Lakhs (41% of total liabilities) in subsidiary HSL Prime Properties.
- Net cash flow from operating activities on a standalone basis deteriorated to -₹1,410.28 Lakhs in FY26 from +₹1,735.34 Lakhs in FY25.
Indrayani Biotech approved its audited consolidated financial results for the quarter and year ended March 31, 2026. For FY26, consolidated revenue stood at Rs 172.84 Cr with a net profit of Rs 2.27 Cr, recovering from a loss of Rs 6.0 Cr in FY25. However, statutory auditors issued a qualified opinion citing Indian GAAP compliance instead of Ind AS for two subsidiaries and unconfirmed balances across loans, receivables, and trade creditors.
- Auditors issued a qualified opinion as two subsidiaries (Matrix Boilers and Kniss Laboratories) prepared financials under Indian GAAP instead of Ind AS.
- Unconfirmed and unreconciled balances flagged across loans, other current assets, and trade receivables.
- Subsidiary HSL Prime Properties lacked balance confirmations for trade creditors worth Rs 61,82,938 (~41% of its liabilities).
- Other auditors covered subsidiaries accounting for ₹11,335.73 lakhs (₹113.36 Cr) in revenue and ₹17,128.01 lakhs in assets.
Indrayani Biotech has scheduled a board meeting for August 17, 2026, to approve its audited financial results for the quarter and full year ended March 31, 2026. The company is coming off a difficult period, with TTM losses of Rs 7 crore and a high debt-to-equity ratio of 1.92. Investors will be closely watching for any recovery in operating margins, which stood at 3.0% TTM, and updates on the company's Rs 146 crore debt burden relative to its Rs 57 crore market cap.
- Board meeting scheduled for August 17, 2026, to approve FY26 audited financials
- Company reported TTM revenue of Rs 151 crore against a market capitalization of Rs 57 crore
- Debt levels are significant at Rs 146 crore, nearly double the net worth of Rs 76 crore
- TTM PAT remains negative at Rs -7 crore, following a net loss of Rs 6 crore in FY25
Indrayani Biotech Ltd has received an order from the Central GST Department dated July 15, 2026, revoking the previous cancellation of its GST registration. The registration had been cancelled on June 09, 2026, with retrospective effect from April 28, 2026, due to the non-filing of returns. The revocation order restores the registration from the original cancellation date, allowing the company to resume normal tax-compliant operations. While the company states there was no impact on operations, the initial cancellation highlights a significant lapse in regulatory compliance.
- GST registration restored via revocation order dated July 15, 2026
- Original cancellation was effective from April 28, 2026
- Initial cancellation order was issued on June 09, 2026, for non-filing of returns
- Restoration is retrospective, covering the period from April 28, 2026
- Company claims no impact on operations during the cancellation period
Indrayani Biotech has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding a tax dispute initiated in March 2025. The ITAT order dated July 14, 2026, quashed the previous order from the First Appellate Authority and remanded the case for fresh adjudication. This follows a series of appeals against an original Assessment Order dated March 26, 2025. While the specific tax demand amount is not disclosed in this filing, the quashing of the previous adverse order provides temporary relief from immediate tax liability enforcement.
- ITAT order dated July 14, 2026, quashes the previous appellate order from March 09, 2026
- Original Assessment Order dates back to March 26, 2025
- Income Tax Appeal No. 1429/CHNY/2026 was filed before the ITAT
- The matter is restored to the First Appellate Authority for fresh adjudication
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
